ABO Histo-Blood Group
ABOgeneBlood-group determinant modulating von Willebrand factor and clotting-factor levels.
Pathway placement
Cascade stepCoagulation & thrombus formation
Confidencehigh
RationaleABO blood group; regulates vWF, fibrinogen, platelet function.
Also acts inPlatelet activation
Druggability
DruggableNo
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableNo
EnsemblENSG00000175164
Type I vs non-Type I discrimination
ScoresNon-Type-I-associated
R — rupture / Type-I—
C — non-Type-I50
A — assay feasibility52
E — evidence strength48
T1DI (composite)8
Specificity differential (R−C)-35
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmian/a
2hypoxemia / respiratory failuren/a
2hypertensive emergencyn/a
2high-demand / peri-operative stressn/a
3sudden cardiac deathn/a
4aPCI-related periproceduraln/a
4bstent thrombosismag 2
4cin-stent restenosismag 1
5CABG-relatedn/a
Coverage: 2/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 3 supporting references. See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood — gene is not a circulating analyte; measure protein product or genotype
Collection tube
K2-EDTA whole blood (lavender-top)
Method / principle
SNP genotyping / sequencing; or immunoassay of encoded protein
Reagent / substrate
Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein
Platform
qPCR / NGS / array
Turnaround · availability
Send-out · Genotyping widely available; protein assay variable
Human genetic evidence
9
GWAS associations
Traits: myocardial infarction
Literature evidence(0)
No direct literature mentions harvested; included via genetic/target evidence.